Envista Holdings Corp: Form 10-Q for the period ended Mar 29, 2024
Filed with the SEC on May 1, 2024 and accepted by EDGAR at May 1, 2024, 16:19 ET.
Management's discussion and analysis
As filed, 31,384 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with other information, including our Condensed Consolidated Financial Statements and related notes included in Part I, Item 1, Financial Information, of this Quarterly Report on Form 10-Q, our consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 10-K”), and Part II, Item 1A, Risk Factors, of this Quarterly Report on Form 10-Q. Unless the context otherwise requires, all references herein to the “Company,” “we,” “us” or “our,” or similar terms, refer to Envista Holdings Corporation and its consolidated subsidiaries.
Certain statements included or incorporated by reference in this Quarterly Report are “forward-looking statements” within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other projected financial measures; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, divestitures, spin-offs, split-offs or other distributions, strategic opportunities, securities offerings, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets we sell into; future regulatory approvals and the timing thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Envista intends or believes will or may occur in the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, the following: the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters, and other risks and uncertainties set forth under “Item 1A. Risk Factors” in the 2023 10-K and this Quarterly Report on Form 10-Q.
Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements contained herein speak only as of the date of this Quarterly Report. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
BASIS OF PRESENTATION
The accompanying Condensed Consolidated Financial Statements present our historical financial position, results of operations, changes in stockholders’ equity and cash flows in accordance with GAAP.
OVERVIEW
General
We provide products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. We help our customers deliver the best possible patient care through industry-leading solutions, technologies, and services. With leading brand names, innovative technology and significant market positions, we are a leading worldwide provider of a broad range of solutions to support implant-based tooth replacements, orthodontic treatments, diagnostic solutions, as well as general dental consumables, equipment and services, and are dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity. Our research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 30 countries across North America, Asia, Europe, the Middle East and Latin America.
We operate in two business segments: Specialty Products & Technologies and Equipment & Consumables. Our Specialty Products & Technologies segment develops, manufactures and markets products primarily related to dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Our Equipment & Consumables segment develops, manufactures and markets products primarily related to dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
For the three months ended March 29, 2024, sales derived from customers outside of the United States were 52.8% compared to the three months ended March 31, 2023, of 52.4%. As a global provider of dental consumables, equipment and services, our operations are affected by worldwide, regional and industry-specific economic and political factors. Given the broad range of dental products, software and services provided and geographies served, we do not use any indices other than general economic trends to predict our overall outlook. Our individual businesses monitor key competitors and customers, including to the extent possible their sales, to gauge relative performance and the outlook for the future.
As a result of our geographic and product line diversity, we face a variety of opportunities and challenges, including rapid technological development in most of our served markets, the expansion and evolution of opportunities in emerging markets, trends and costs associated with a global labor force, consolidation of our competitors and increasing regulation. We operate in a highly competitive business environment in most markets, and our long-term growth and profitability will depend in particular on our ability to expand our business in emerging geographies and emerging market segments, identify, consummate and integrate appropriate acquisitions, develop innovative and differentiated new products and services, expand and improve the effectiveness of our sales force, continue to reduce costs and improve operating efficiency and quality and effectively address the demands of an increasingly regulated global environment. We are making significant investments to address the rapid pace of technological change in our served markets and to globalize our manufacturing, research and development and customer-facing resources (particularly in emerging markets and our dental implant business) in order to be responsive to our customers throughout the world and improve the efficiency of our operations.
Key Trends and Conditions Affecting Our Results of Operations
General Economic Conditions
In addition to industry-specific factors, we, like other businesses, face challenges related to global economic conditions, including inflation, interest rates, fluctuating foreign currency exchange rates, slow economic growth, and continuing supply chain disruptions. Dental costs are largely out-of-pocket for the consumer and thus utilization rates can vary significantly depending on economic growth. While many of our products are considered necessary by patients regardless of the economic environment, certain products and services that support discretionary dental procedures may be more susceptible to changes in economic conditions.
Foreign Currency Exchange Rates
On a period-over-period basis, currency exchange rates negatively impacted reported sales by 1.0% for the three months ended March 29, 2024, compared to the comparable period of 2023, primarily due to the strength of the U.S. dollar against most major currencies. Any future strengthening of the U.S. dollar against major currencies would negatively impact our sales and results of operations for the remainder of the year, and any weakening of the U.S. dollar against major currencies would positively impact our sales and results of operations for the remainder of the year.
Pricing Controls
Certain countries, as well as some private payors, also control the price of health care products, directly or indirectly, through reimbursement, payment, pricing or coverage limitations, tying reimbursement to outcomes or (in the case of governmental entities) compulsory licensing. For example, China has implemented volume-based procurement policies, a series of centralized reforms instituted in China on both a national and regional basis that has resulted in significant price cuts for medical and dental consumables.
Russia-Ukraine Conflict
Russia’s invasion of Ukraine and the global response to this invasion, including sanctions imposed by the U.S. and other countries, could have an adverse impact on our business, including our ability to market and sell products in the affected regions, potentially heightening our risk of cyber security attacks, impacting our ability to enforce our intellectual property rights in Russia, creating disruptions in the global supply chain, and potentially having an adverse impact on the global economy, financial markets, energy markets, currency rates and otherwise. While we are experiencing volatility in sales from this region, Russia’s invasion of Ukraine did not have a material impact on our overall financial position or results of operations as of and for the three months ended March 29, 2024 and March 31, 2023.
Israel-Hamas War
In response to the attacks in Israel and the subsequent hostilities, we continue to monitor the social, political, and economic environment in Israel and in the region for any impact to our operations. Revenue generated from Israel is approximately $12 million annually. We also maintain a production facility in Israel related to our Alpha-Bio Tech Implant brand. While we have experienced some volatility in the region, the Israel-Hamas War and related hostilities have not had a material impact on our business.
Seasonal Nature of Business
General economic conditions impact our business and financial results, and certain of our businesses experience seasonal and other trends related to the end markets and regions that they serve. For example, sales of capital equipment have historically been stronger in the fourth calendar quarter. However, as a whole, we are not subject to material seasonality.
Non-GAAP Measures
In order to establish period-to-period comparability, we include the non-GAAP measure of core sales in this report. References to the non-GAAP measure of core sales (also referred to as core revenues or sales/revenues from existing businesses) refer to sales calculated according to GAAP, but excluding:
- sales from acquired businesses for one year from the acquisition date;
- sales from discontinued products; and
- the impact of currency translation.
We exclude sales from acquired businesses in order to provide accurate year over year comparisons. Sales from discontinued products includes major brands or major products that we have made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which we (1) are no longer manufacturing, (2) are no longer investing in the research or development of, and (3) expect to discontinue all significant sales of within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. We exclude sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers.
The portion of sales attributable to currency translation is calculated as the difference between:
- the period-to-period change in sales; and
- the period-to-period change in sales after applying current period foreign exchange rates to the prior year period.
Core sales growth should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies. We believe that reporting the non-GAAP financial measure of core sales growth provides useful information to investors by helping identify underlying growth trends in our on-going business and facilitating comparisons of our sales performance with our performance in prior and future periods and to our peers. We also use core sales growth to measure our operating and financial performance. We exclude the effect of currency translation from core sales because currency translation is not under our control, is subject to volatility and can obscure underlying business trends.
RESULTS OF OPERATIONS
All comparisons, variances, increases or decreases discussed below are for the three months ended March 29, 2024, compared to the three months ended March 31, 2023.
($ in millions)
| Three Months Ended March 29, 2024 | March 31, 2023 | % Change | |||
|---|---|---|---|---|---|
| Sales | $623.6 | 100.0% | $627.2 | 100.0% | (0.6)% |
| Cost of sales | 267.3 | 42.9% | 264.5 | 42.2% | 1.1% |
| Gross profit | 356.3 | 57.1% | 362.7 | 57.8% | (1.8)% |
| Operating costs: | |||||
| Selling, general and administrative (“SG&A”) expenses | 284.9 | 45.7% | 266.1 | 42.4% | 7.1% |
| Research and development (“R&D”) expenses | 23.3 | 3.7% | 24.5 | 3.9% | (4.9)% |
| Operating profit | 48.1 | 7.7% | 72.1 | 11.5% | (33.3)% |
| Nonoperating income (expense): | |||||
| Other income, net | 0.1 | —% | 0.3 | —% | (66.7)% |
| Interest expense, net | (12.9) | (2.1)% | (16.7) | (2.7)% | (22.8)% |
| Income before income taxes | 35.3 | 5.7% | 55.7 | 8.9% | (36.6)% |
| Income tax expense | 11.7 | 1.9% | 11.9 | 1.9% | (1.7)% |
| Net income | $23.6 | 3.8% | $43.8 | 7.0% | (46.1)% |
| Effective tax rate | 33.1% | 21.4% |
GAAP Reconciliation
Sales and Core Sales Growth
| % Change Three Month Period Ended March 29, 2024 vs. Comparable 2023 Period | |
|---|---|
| Total sales growth (GAAP) | (0.6)% |
| Plus the impact of: | |
| Currency exchange rates | 1.0% |
| Core sales growth (non-GAAP) | 0.4% |
Sales for the three months ended March 29, 2024 decreased 0.6% while core sales growth increased by 0.4% for the comparable period in 2023. An increase in sales volume positively impacted sales by 0.6% on a period-over-period basis, partially offset by a decrease in sales price of 0.2%. Sales decreased due to lower demand in North America, partially offset by an increase in China.
COST OF SALES AND GROSS PROFIT MARGIN
($ in millions)
| Three Months Ended March 29, 2024 | March 31, 2023 | |
|---|---|---|
| Cost of sales | $267.3 | $264.5 |
| Gross profit margin | 57.1% | 57.8% |
26
The increase in cost of sales during the three months ended March 29, 2024 as compared to the comparable period in 2023, was primarily due to unfavorable product mix.
The decrease in gross profit margin percentage during the three months ended March 29, 2024, as compared to the comparable period in 2023, was primarily due to unfavorable sales price and product mix, partially offset by an increase in sales volume.
OPERATING EXPENSES
($ in millions)
| Three Months Ended March 29, 2024 | March 31, 2023 | |
|---|---|---|
| Selling, general and administrative expenses | $284.9 | $266.1 |
| Research and development expenses | $23.3 | $24.5 |
| SG&A as a % of sales | 45.7% | 42.4% |
| R&D as a % of sales | 3.7% | 3.9% |
The increase in SG&A expenses as a percentage of sales for the three months ended March 29, 2024 as compared to the comparable period of 2023, was primarily due to higher sales and marketing and compensation spend, partially offset by decreased amortization of intangible assets.
R&D expenses as a percentage of sales for the three months ended March 29, 2024, was consistent with the comparable period in 2023.
INTEREST COSTS AND FINANCING
Interest costs were $12.9 million and $16.7 million for the three months ended March 29, 2024 and March 31, 2023, respectively. The decrease in interest costs for the three months ended March 29, 2024 as compared to the comparable period of 2023 was primarily due to higher returns on cash and cash equivalents, partially offset by higher variable rate term borrowings and interest rates.
INCOME TAXES
| Three Months Ended March 29, 2024 | March 31, 2023 | |
|---|---|---|
| Effective tax rate | 33.1% | 21.4% |
Our effective tax rate for the three months ended March 29, 2024 was 33.1% compared to 21.4% in 2023. The change in the effective rate was primarily due to the impact of a valuation allowance against certain U.S. interest carryforwards.
RESULTS OF OPERATIONS - BUSINESS SEGMENTS
Specialty Products & Technologies
Our Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products.
Specialty Products & Technologies Selected Financial Data
($ in millions)
| Three Months Ended March 29, 2024 | March 31, 2023 | |
|---|---|---|
| Sales | $408.7 | $410.0 |
| Operating profit | $44.2 | $71.1 |
| Operating profit as a % of sales | 10.8% | 17.3% |
27
Sales and Core Sales Growth
| % Change Three Month Period Ended March 29, 2024 vs. Comparable 2023 Period | |
|---|---|
| Total sales growth (GAAP) | (0.3)% |
| Plus the impact of: | |
| Currency exchange rates | 1.1% |
| Core sales growth (non-GAAP) | 0.8% |
Sales
Sales for the three months ended March 29, 2024 decreased 0.3% while core sales growth increased by 0.8% compared to the comparable period in 2023. An increase in sales volume positively impacted sales by 1.1% on a period-over-period basis, partially offset by a decrease in sales price of 0.3%. The decrease in sales is primarily due to lower demand in North America, partially offset by growth in China and Europe.
Operating Profit
Operating profit margin was 10.8% for the three months ended March 29, 2024, as compared to an operating profit margin of 17.3% for the comparable period of 2023. For the three months ended March 29, 2024, the decrease was primarily due to unfavorable product mix and sales price, and higher costs related to our long-term growth initiatives, partially offset by an increase in sales volume.
EQUIPMENT & CONSUMABLES
Our Equipment & Consumables segment primarily develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
Equipment & Consumables Selected Financial Data
($ in millions)
| Three Months Ended March 29, 2024 | March 31, 2023 | |
|---|---|---|
| Sales | $214.9 | $217.2 |
| Operating profit | $35.6 | $32.5 |
| Operating profit as a % of sales | 16.6% | 15.0% |
Sales and Core Sales Growth
| % Change Three Month Period Ended March 29, 2024 vs. Comparable 2023 Period | |
|---|---|
| Total sales growth (GAAP) | (1.1)% |
| Plus the impact of: | |
| Currency exchange rates | 0.9% |
| Core sales growth (non-GAAP) | (0.2)% |
Sales
Sales and core sales growth for the three months ended March 29, 2024 decreased 1.1%, and 0.2%, respectively, compared to the comparable period in 2023. A decrease in sales volume negatively impacted sales by 0.1% on a period-over-period basis, combined with a decrease in sales price of 0.1%. The decrease in sales is primarily due to lower demand from Europe, partially offset by higher demand in North America.
Operating Profit
Operating profit margin was 16.6% for the three months ended March 29, 2024, as compared to an operating profit margin of 15.0% for the comparable period of 2023. The increase in operating profit margin for the three months ended March 29, 2024 was primarily due to favorable product mix, period-over-period savings associated with productivity improvements and decreased amortization of intangible assets, partially offset by unfavorable sales volume and price.
LIQUIDITY AND CAPITAL RESOURCES
We assess our liquidity in terms of our ability to generate cash to fund our operating and investing activities. We continue to generate substantial cash from operating activities and believe that our operating cash flow and other sources of liquidity are sufficient to allow us to manage our capital structure on a short-term and long-term basis and continue investing in existing businesses and consummating strategic acquisitions.
Following is an overview of our cash flows and liquidity:
Overview of Cash Flows and Liquidity
| Three Months Ended March 29, 2024 | March 31, 2023 | |
|---|---|---|
| Net cash provided by operating activities | $40.3 | $3.1 |
| Payments for additions to property, plant and equipment | $(11.0) | $(17.5) |
| All other investing activities, net | 0.3 | (4.5) |
| Net cash used in investing activities | $(10.7) | $(22.0) |
| Proceeds from stock option exercises | 1.3 | $4.6 |
| Tax withholding payment related to net settlement of equity awards | (3.3) | (6.1) |
| All other financing activities | (0.6) | — |
| Net cash used in financing activities | $(2.6) | $(1.5) |
Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period due to working capital needs and the timing of payments for income taxes, restructuring activities, pension funding and other items impacting reported cash flows.
Net cash provided by operating activities was $40.3 million during the three months ended March 29, 2024, as compared to net cash provided by operating activities of $3.1 million for the comparable period of 2023. The increase in cash provided by operating activities during the three months ended March 29, 2024 is primarily due to timing of vendor payments combined with lower year end incentive compensation paid in the current period, partially offset by lower net income as compared to 2023.
Investing Activities
Cash flows relating to investing activities consist primarily of cash used for capital expenditures and acquisitions. Capital expenditures are made primarily for increasing capacity, replacing equipment, supporting new product development and improving information technology systems.
Net cash used in investing activities was $10.7 million for the three months ended March 29, 2024, as compared to net cash used in investing activities of $22.0 million for the comparable period in 2023, primarily due to the lower payments for purchases of property, plant and equipment.
Financing Activities and Indebtedness
Cash flows relating to financing activities consist primarily of cash flows associated with debt borrowings and the issuance of common stock.
Net cash used by finance activities was $2.6 million for the three months ended March 29, 2024 compared to net cash used by financing activities of $1.5 million for the comparable period of 2023, primarily due to lower cash proceeds from stock option exercises.
For a description of our outstanding debt as of March 29, 2024, refer to Note 11 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
We intend to satisfy any short-term liquidity needs that are not met through operating cash flow and available cash primarily through our revolving credit facility.
Cash and Cash Requirements
As of March 29, 2024, we held $948.5 million of cash and cash equivalents that were held on deposit with financial institutions. Of this amount, $326.2 million was held within the United States and $622.3 million was held outside of the United States. We will continue to have cash requirements to support working capital needs, capital expenditures and acquisitions, pay interest and service debt, pay taxes and any related interest or penalties, fund our restructuring activities as required and support other business needs. We generally intend to use available cash, internally generated funds and our revolving credit facility to meet these cash requirements, but in the event that additional liquidity is required, particularly in connection with acquisitions, we may need to enter into new credit facilities or access the capital markets. We may also access the capital markets from time to time to take advantage of favorable interest rate environments or other market conditions. However, there is no guarantee that we will be able to obtain alternative sources of financing on commercially reasonable terms or at all. See “Item 1A. Risk Factors—Risks Related to Our Business” in our 2023 10-K.
Generally, cash and cash equivalents held in these financial institutions may be withdrawn or redeemed at face value, and therefore minimal credit risk exists with respect to them. Nonetheless, deposits with these financial institutions exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits or similar limits in foreign jurisdictions, to the extent such deposits are even insured in such foreign jurisdictions. While we monitor on a systematic basis the cash and cash equivalent balances in the operating accounts and adjust the balances as appropriate, these balances could be impacted if one or more of the financial institutions with which we deposit our funds fails or is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss of principal or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our cash and cash equivalents will not be affected if the financial institutions where we hold our cash and cash equivalents fail.
While repatriation of some cash held outside the United States may be restricted by local laws, most of our foreign cash could be repatriated to the United States. Following enactment of the Tax Cut and Jobs Act of 2017 (“TCJA”) and the associated transition tax, in general, repatriation of cash to the United States can be completed with no incremental U.S. tax; however, repatriation of cash could subject us to non-U.S. jurisdictional taxes on distributions. The cash that our non-U.S. subsidiaries hold for indefinite reinvestment is generally used to finance foreign operations and investments, including acquisitions. The income taxes, if any, applicable to such earnings including basis differences in our foreign subsidiaries are not readily determinable.
As of March 29, 2024, we believe that we have sufficient sources of liquidity to satisfy our cash needs over the next 12 months and beyond, including our cash needs in the United States.
Off-Balance Sheet Arrangements
There were no material changes to the Company’s off-balance sheet arrangements described in the 2023 10-K that would have a material impact on the Company’s Condensed Consolidated Financial Statements.
Debt Financing Transactions
For a description of our outstanding debt as of March 29, 2024, refer to Note 11 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
Critical Accounting Estimates
There were no material changes to our critical accounting estimates described in the 2023 10-K that have had a material impact on our Condensed Consolidated Financial Statements.
Market risk
As filed, 352 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures About Market Risk,” in our 2023 10-K. There were no material changes to this information reported in our 2023 10-K during the quarter ended March 29, 2024.
Controls and procedures
As filed, 964 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our President and Chief Executive Officer, and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our President and Chief Executive Officer, and Principal Financial Officer, have concluded that, as of the end of such period, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 29, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 1,811 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our 2023 10-K, which could materially affect our business, financial position, or future results of operations. The risks described in our 2023 10-K, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial position, or future results of operations. The risk factor set forth below updates, and should be read together with, the risk factors described in our 2023 10-K.
The loss of members of our senior management and the resulting management transition might have an adverse impact on our future operating results.
On April 15, 2024, we announced the appointment of Paul Keel as our President and Chief Executive Officer, effective as of May 1, 2024. Mr. Keel was also appointed to our Board of Directors, effective as of May 1, 2024. In connection with this appointment and pursuant to the transition letter agreement dated February 22, 2024 between the Company and Amir Aghdaei, Mr. Aghdaei resigned from his position as a director of the Board effective May 1, 2024 and will transition to the role of senior advisor to support the Chief Executive Officer transition on that date. Additionally, as previously reported, we have experienced several executive officer departures over the past year, including our Chief Financial Officer. These leadership transitions along with other senior management changes may be inherently difficult to manage. If we do not successfully manage this transition process, it could be viewed negatively by our customers, employees or investors and could have a negative impact on our business, results of operations and financial condition.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-29 | $623.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-01-01 to 2024-03-29 | $267.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-01-01 to 2024-03-29 | $356.3m | us-gaap:GrossProfit |
| Research and development | 3 months2024-01-01 to 2024-03-29 | $23.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-01-01 to 2024-03-29 | $284.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-01-01 to 2024-03-29 | $48.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-29 | $12.9m | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-29 | $11.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-29 | $23.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-29 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-29 | $0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-29 | 173,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-29 | $40.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-01-01 to 2024-03-29 | $11.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-29 | $948.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-29 | $1.77bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-29 | $6.56bn | us-gaap:Assets |
| Current liabilities | At period end2024-03-29 | $781.3m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2024-03-29 | $1.39bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-03-29 | $115.5m | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2024-03-29 | $115.5m | us-gaap:ShortTermBorrowings |
Source: SEC EDGAR, the filing index for accession 0001757073-24-000039. Last ingested by Listed: Nov 14, 2026, 11:59 ET. Listed shows no prices and gives no investment advice.